Aster DM Quality Care Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Merger creates a top-three Indian hospital chain: Aster will combine with Blackstone-backed QCIL to form a 38-hospital, 10,000+ bed platform across nine states, with shareholder approval secured at 99.99%.
• India business delivered 15% revenue growth in 9M FY25, driven by a 12% ARPOB increase and 4% rise in occupied beds, while adjusted PAT grew 65% to INR 251 crore.
• Kerala, the core cluster, had a soft quarter: occupancy in mature hospitals dipped to 61% as 250 new beds came online and seasonal factors reversed, but management says January is already showing restoration.
• Margin expansion story intact despite a QoQ blip: 9M FY25 EBITDA margin reached 19.5% vs 16.6% a year ago; the Q3 dip was a one-off driven by oncology mix, with hospital segment margins guided to 24% by FY27.
• What to watch next quarter: the pace of Kerala's recovery, the CCI and NCLT approval timeline for the QCIL merger, and whether the Whitefield Block D commissioning stays on track for May/June.

The QCIL Merger: Scale, Structure, and Timeline

• Deal structure: Aster will first acquire a 5% stake in QCIL from Blackstone and TPG in exchange for primary share issuance representing a 3.6% stake in Aster; QCIL will then be merged into Aster through a scheme of amalgamation.
• Strategic outcome: The combined entity becomes one of the top three hospital chains in India with 38 hospitals and over 10,000 beds, extending Aster's footprint across nine Indian states.
• Regulatory path: The merger application has been filed with the CCI and stock exchanges; completion requires no-objection certificates from stock exchanges, CCI approval, and NCLT approval.
• Information barrier: Management declined to share any performance data on CARE hospitals (QCIL) or pro forma joint financials, citing legal advice that the two companies cannot exchange information until certain regulatory approvals are received.
• Pre-merger preparation: Management stated they would not jump the gun on integration planning; prep work can begin once initial approvals are in place, but full integration cannot start until the merger is complete.

Alisha Moopen: "This merger will create one of the top three hospital chains in India."

Kerala: The Quarter's Drag and the Strategic Pivot

• Occupancy drop explained: Mature hospital occupancy fell to 61%, dragged down by roughly 250 beds added in the Kerala region: 100 beds in Kannur at the end of Q2 FY25, 100 beds in Aster Medcity in Q3 FY25, and 25 beds each in Kottakkal and PMF.
• Seasonal reversal: The flu season ended in Q2 this year versus extending into Q3 last year, reducing footfall; Karnataka cluster was similarly affected by the flu season shift.
• International patient slowdown: Footfalls from GCC and Maldives, key regions for Kerala, reduced significantly during the quarter.
• Leadership transition: The main flagship unit at Medcity saw leadership changes; a new CEO, Dr. Jaydev, is now in place, and a new COO has been in the system for two months, with the chairman directly involved with clinicians.
• Strategic shift underway: Management is deliberately moving Kerala away from a volume-based approach toward improving ARPOB and quality of occupancy, choosing not to play the price game as more corporate competitors enter the market.
• Early recovery signal: January is already showing traction, and management expects the muted growth to be very temporary.

Alisha Moopen: "Earlier, we were talking much more volume based. So, that was where the strategic shift in terms of moving some of the lower schemes and all has happened. So that's kind of the direction with Kerala also going forward because you're seeing more and more corporates coming into Kerala. You're seeing that there will be pressure on the volume. So, we thought with our market leadership in Kerala, we should be focusing more on improving the ARPOB, quality of the occupancy."

Cluster-Level Performance

• Karnataka & Maharashtra margin driver: ARPOB increase came from case mix improvement, especially high-end cases at Whitefield; surgical numbers rose in oncology and neuro; ALOS came down by roughly 0.2 days.
• Telangana & Andhra ramp-up: New clinicians onboarded at Prime hospital; the cluster still has margin catch-up potential relative to more mature clusters.
• Q3 seasonality context: Q2 is the peak season due to rains, dengue, and flus; from September onward, festivals start, medical cases decline, and doctors travel, making Q3 always muted compared to other quarters; Q4 typically goes up.

Margin Bridge and the Oncology Glitch

• 9M FY25 margin expansion: Consolidated EBITDA margin reached 19.5%, up from 16.6% a year ago, fueled by operational efficiencies including ALOS reduction, cost optimization, and enhanced lab EBITDA; material costs decreased to 20.7% from 22.3%.
• Hospital & clinics segment: Operating EBITDA margins improved to 22.3% from 19.5%; mature hospitals achieved 25% margin, up from 22%, with ROCE of 36%.
• Q3 QoQ margin dip: Material cost increased roughly 1% due to oncology growth at 28%, which carries higher material cost; without that mix effect, Q3 would have been above 20% EBITDA margin; management described it as a "QoQ glitch."
• Further efficiency room: Management sees another 50-100 bps available in material cost efficiency, with non-medical consumables optimization planned for next year.
• ROCE improvement: Overall ROCE reached 19.4%, a 470 bps YoY increase; hospital and clinics ROCE hit 25.8%, up from 20.6%; matured hospitals ROCE reached 35.7%, an over 700 bps increase.

Sunil Kumar: "I expect that by FY26 - 27, we should be somewhere near 21%. And from the hospital clinic segment, which we are today at 22.3 - 22.4%, there you can expect around 24% margin. These are all very sustainable margins which we can reach and continue to be there."

Labs, Pharmacy, and the Digital Pivot

• Lab business turnaround: The labs segment reached breakeven in Q4 FY24, improved margins to 3.4% in Q1 FY25, and hit 9.4% in Q3 FY25, driven by 27% YoY growth in external business, improved operating leverage, and material cost efficiencies.
• Strategic curtailment: Labs and pharmacy operations have been curtailed to states where Aster hospitals are strong; underperforming pharmacy stores were closed after bleeding cash previously.
• Pharmacy store count: Will be maintained at roughly 200-225 stores; management stated they will not go below 200, and are moving out of bad locations where yield per day per store cannot be driven above a benchmark level.
• Pharmacy breakeven timeline: Expected sometime in the last quarter of FY26.
• Non-Aster lab growth ambition: Expected to grow more than 35-40% in the coming year.
• Digital app rollout: The Aster Health app launched in January for CMI; expansion to all hospitals is targeted for March; labs and pharmacy integration will follow as phase two sometime in Q3 FY26.
• Wholesale pharmacy de-emphasis: Expected to become smaller and smaller; not seen as an important growth area.

Sunil Kumar: "We will, for very sure will not go below 200. We will maintain about 200. Also, wherever the locations are bad, and we think that we are not able to drive the yield per day per store above certain benchmark level, then we are moving."

Capacity Expansion and Capital Allocation

• Bed addition plan: Approximately 1,700 beds to be added, increasing total capacity to over 6,800 beds by FY27; the majority will be brownfield expansions to ensure no dilution in margins.
• Key brownfield projects: Aster Medcity expanding to roughly 950 beds, Aster CMI to roughly 850 beds, Aster Whitefield to roughly 500 beds.
• Whitefield Block D: 150 beds now expected operational by May/June (Q1 FY26), delayed from the original Q4 FY25 timeline; at full maturity, this block can approach a near-30% margin.
• Other upcoming capacity: A 150-bed women and children block operational in H1 FY26; a 260-bed Kasargod hospital expected in H1 FY26; roughly 75 beds of brownfield expansion at Ongole expected in FY26.
• Organic funding capacity: Management stated that with existing cash flow, Aster can add 1,500-2,000 brownfield or asset-light beds over the next three to four years without adding any more debt.
• Inorganic appetite: Management will look at inorganic opportunities if something comes up, but the primary expansion path is organic.
• Interim dividend: Declared as the first dividend since listing in 2018, other than a special dividend in April and the final dividend for FY24.

Sunil Kumar: "With existing cash flow, we're able to manage the expansion plans and with the additional coming in, at least in next three to four years' time, if you look at, we can even add more than 1,500-2,000 beds, I'm talking about the brownfield or the asset light beds which we can add without adding any more debt."

Guidance & Commitments

Key Metrics